Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
November 3, 2021 4:05 PM EDTSEATTLE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2021.
We are pleased to deliver another quarter of strong growth with continued momentum across research, diagnostic and drug discovery, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. Achievements during the quarter mark important advancements in the evolution of our immune medicine platform as a clinical product development engine.
... More